Turning a corner: Private market posts best month in yearsCore private market metrics suggest positive momentum is brewing and investor sentiment is improving
Turning a corner: Private market posts best month in years
Trading
Data
Solutions
Insights
About
Boundless Bio, founded in 2018, is a biopharmaceutical company that develops novel cancer therapeutics seeking to understand and treat intractable cancers. Boundless Bio aims to interrogate extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers. Boundless Bio is headquartered in La Jolla, California.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 5/16/2023 | Series C | $100MM raised | $XXX.XX | $XXX.XX |
| 4/28/2021 | Series B | $105.59MM raised | $XXX.XX | $XXX.XX |
| 9/19/2019 | Series A | $46.47MM raised | $XXX.XX | $XXX.XX |
